


 Substitute Form PTO-1449  
(Modified)

 U.S. Department of Commerce  
Patent and Trademark Office

 Attorney's Docket No.  
20750-007US1

 Application No.  
10/541,657

**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

(37 CFR 1.98(b))

 Applicant  
Arena Pharmaceuticals, Inc.

 Filing Date  
March 3, 2006

 Group Art Unit  
1624

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AI	EP 1287133	03/05/2003	Europe				
	AJ							
	AK							
	AL							
	AM							

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AN	Abstract #107, p.56, <i>Toward Understanding Islet Biology</i> , January 21, 2003 – January 26, 2003, Keystone, Colorado.
	AO	Abstract #112, p.42, <i>Diabetes Mellitus: Molecular Mechanisms, Genetics and New Therapies</i> , January 27, 2005 – February 2, 2005, Keystone, Colorado.
	AP	Abstract #228, p.54, <i>Diabetes Mellitus: Molecular Mechanisms, Genetics and New Therapies</i> , January 27, 2005 – February 2, 2005, Keystone, Colorado.
	AQ	Abstract #117 & Poster, <i>Diabetes: Molecular Genetics, Signaling Pathways and Integrated Physiology</i> , January 14, 2007 – January 19, 2007, Keystone, Colorado
	AR	Abstract #230 & Poster, <i>Diabetes: Molecular Genetics, Signaling Pathways and Integrated Physiology</i> , January 14, 2007 – January 19, 2007, Keystone, Colorado
	AS	Chu et al., "A role for $\beta$ -cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release," <i>Endocrinology</i> (2007) 148:2601-2609.
	AT	Fyfe et al., <i>Diabetes</i> (2007) 56(Supplement 1):A142 (Abstract #532-P).

Examiner Signature /Jeffrey Murray/

Date Considered 02/18/2009

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

Substitute Disclosure Form (PTO 1449)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-007US1	Application No. 10/541,657
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Arena Pharmaceuticals, Inc.	
		Filing Date March 3, 2006	Group Art Unit 1624

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AU	Overton et al., "Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents," <i>Cell Metabolism</i> (2006) 3:167-175.
	AV	Soga et al., "Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor," <i>Biochem Biophys Res Commun</i> (2005) 326:744-751.

Examiner Signature /Jeffrey Murray/	Date Considered 02/18/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./